Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.

J Immunother Cancer · 2026 · PMC13157761 · PMID 42103356

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Assessment of HLA-E and NKG2A indicated numerically higher HLA-E and NKG2A levels in patients with PR who had received combination treatment, but the differences did not reach statistical significance ( online supplemental figure 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.